Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice

被引:37
作者
Liu, ML
Von Lintig, FC
Liyanage, M
Shibata, MA
Jorcyk, CL
Ried, T
Boss, GR
Green, JE
机构
[1] NCI, Div Basic Sci, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA
[2] NIH, Natl Human Genome Res Inst, Bethesda, MD USA
[3] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
关键词
CGH; Ki-ras; gene amplification; MAP kinase; mammary gland tumor; transgenic mice; Ras-bound GTP and GDP;
D O I
10.1038/sj.onc.1202456
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have previously documented that transgenic mice expressing SV40 Tag regulated by the rat prostatic steroid-binding protein C3(1) 5'-flanking region display multistage mammary tumorigenesis. To delineate genetic changes associated with mammary tumor progression, comparative genomic hybridization (CGH) was performed. CGH revealed a consistent gain of the telomeric region of chromosome 6, This region contains the Ki-ras proto-oncogene, Analyses of genomic DNA by Southern blot demonstrated up to 40-fold amplification of the Ki-ras gene. Ki-ras amplification was detected in 12, 46 and 68% of tumors from 4, 5 and 6 month old mice, respectively, whereas no amplifications were found in any preneoplastic mammary tissues. Tumors bearing Ki-ras gene amplification exhibited high levels of Ki-ras RNA and protein, The over-expressed Ki-Ras protein in these tumors appeared functionally active as indicated by the elevated MAP kinase activity, These data demonstrate that while Ki-ras amplification might not be an early event, there is a strong association between Ki-ras amplification and over-expression and mammary tumor progression in this model. This study also shows that CGH is a powerful and useful technique for identifying chromosomal copy number changes during tumor progression, and that this model may provide a predictable in vivo system for studying gene amplification.
引用
收藏
页码:2403 / 2411
页数:9
相关论文
共 34 条
[1]  
ALDAZ CM, 1993, CANCER RES, V53, P5339
[2]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[3]   SEQUENCE-SPECIFIC DNA-BINDING BY THE C-MYC PROTEIN [J].
BLACKWELL, TK ;
KRETZNER, L ;
BLACKWOOD, EM ;
EISENMAN, RN ;
WEINTRAUB, H .
SCIENCE, 1990, 250 (4984) :1149-1151
[4]   THE CYTOPLASMIC PROTEIN GAP IS IMPLICATED AS THE TARGET FOR REGULATION BY THE RAS GENE-PRODUCT [J].
CALES, C ;
HANCOCK, JF ;
MARSHALL, CJ ;
HALL, A .
NATURE, 1988, 332 (6164) :548-551
[5]   ACTIVATION OF KI-RAS 2 GENE IN HUMAN-COLON AND LUNG CARCINOMAS BY 2 DIFFERENT POINT MUTATIONS [J].
CAPON, DJ ;
SEEBURG, PH ;
MCGRATH, JP ;
HAYFLICK, JS ;
EDMAN, U ;
LEVINSON, AD ;
GOEDDEL, DV .
NATURE, 1983, 304 (5926) :507-513
[6]  
CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3
[7]  
CZERNIAK B, 1989, CANCER, V63, P2008, DOI 10.1002/1097-0142(19890515)63:10<2008::AID-CNCR2820631024>3.0.CO
[8]  
2-D
[9]   SOMATIC GENETIC CHANGES IN HUMAN BREAST-CANCER [J].
DEVILEE, P ;
CORNELISSE, CJ .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1994, 1198 (2-3) :113-130
[10]   EXPRESSION OF H-RAS CORRELATES WITH METASTATIC POTENTIAL - EVIDENCE FOR DIRECT REGULATION OF THE METASTATIC PHENOTYPE IN 10T1/2 AND NIH 3T3 CELLS [J].
EGAN, SE ;
MCCLARTY, GA ;
JAROLIM, L ;
WRIGHT, JA ;
SPIRO, I ;
HAGER, G ;
GREENBERG, AH .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (02) :830-837